TScan Therapeutics(US:TCRX)2025-11-12 12:15Financial Performance - Revenue for Q3 2025 was $2.5 million, a 150% increase from $1.0 million in Q3 2024, primarily due to research activities under a collaboration agreement with Amgen[9] - R&D expenses for Q3 2025 were $31.7 million, up from $26.3 million in Q3 2024, driven by increased manufacturing and clinical activities[10] - G&A expenses for Q3 2025 were $7.9 million, compared to $7.4 million in Q3 2024, mainly due to personnel costs[11] - Net loss for Q3 2025 was $35.7 million, compared to $29.9 million in Q3 2024, including net interest income of $1.3 million[12] - Cash, cash equivalents, and marketable securities as of September 30, 2025, were $184.5 million, expected to fund operations into the second half of 2027[12] Clinical Development - The pivotal trial for TSC-101 is expected to begin in Q2 2026, following an agreement with the FDA on the trial design[3] - The company plans to present updated clinical data from the ALLOHA Phase 1 heme trial at the ASH Annual Meeting on December 6, 2025[5] - The company has paused enrollment in the PLEXI-T trial to focus on preclinical development for solid tumors[15] Manufacturing and Product Development - A commercial-ready manufacturing process has been implemented, reducing manufacturing time by five days and lowering costs[4] - Plans to submit IND applications for two additional TCR-T product candidates in Q4 2025 to expand HLA coverage of the heme program[7]